Treatment of Chronic Migraine: A 3-Month Comparator Study of Naproxen Sodium vs SumaRT/Nap
Article first published online: 10 SEP 2013
© 2013 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 54, Issue 1, pages 80–93, January 2014
How to Cite
Cady, R., Nett, R., Dexter, K., Freitag, F., Beach, M.E. and Manley, H. R. (2014), Treatment of Chronic Migraine: A 3-Month Comparator Study of Naproxen Sodium vs SumaRT/Nap. Headache: The Journal of Head and Face Pain, 54: 80–93. doi: 10.1111/head.12210
Conflicts of Interest: Dr. Roger Cady currently serves on several advisory boards: Allergan, Astellas, MAP Pharmaceuticals, Merck & Co, Inc., Novartis, Ortho-McNeil Neurologics, and Zogenix. He also receives research grants from Allergan, Boston Scientific, Bristol Myers, GlaxoSmithKline, Merck & Co, Inc., OptiNose, PuraMed Bioscience, and Zogenix. Dr. Cady provided consulting services for Allergan, Astellas, GlaxoSmithKline, Merck & Co., Inc., and Ortho-McNeil Neurologics. Dr. Robert Nett has served as a consultant and/or served on advisory boards for multiple pharmaceutical companies. Dr. Kent Dexter has nothing to disclose. Dr. Fred Freitag is on the speaker's bureau for Allergan Pharmaceuticals, Nautilus Neuroscience, and Zogenix Pharmaceuticals. He also is an advisory board/consultant for Allergan Pharmaceuticals and MAP Pharmaceuticals and received grant support from GlaxoSmithKline. Ms. M.E. Beach and Ms. Heather Manley have nothing to disclose.
This study was sponsored by a grant from GlaxoSmithKline, Research Triangle Park, North Carolina.
Trial Registration: ClinicalTrials.gov NCT01090050.
Study approved by Sterling IRB.
- Issue published online: 8 JAN 2014
- Article first published online: 10 SEP 2013
- Manuscript Accepted: 4 JUL 2013
- GlaxoSmithKline, Research Triangle Park, North Carolina
This article has been cited by:
- 2Headache and Migraine Biology and Management, 2015,, ,